非小细胞肺癌分子靶向治疗及其耐药

国际肿瘤学杂志››2016,Vol. 43››Issue (1): 45-48.doi:10.3760/cma.j.issn.1673-422X.2016.01.013

非小细胞肺癌分子靶向治疗及其耐药

张钰,周建国,马虎

563000 遵义医学院附属医院胸部肿瘤科

收稿日期:2015-01-19出版日期:2016-01-08发布日期:2015-12-03
通讯作者:马虎 E-mail:mahuab@163.com
基金资助:

国家自然科学基金（81360351）

Molecular targeted therapy for non-small cell lung cancer and drug resistance

Zhang Yu, Zhou Jianguo, Ma Hu

Department of Chest Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China

Received:2015-01-19Online:2016-01-08Published:2015-12-03
Contact:Ma Hu E-mail:mahuab@163.com
Supported by:

National Natural Science Foundation of China (81360351)

摘要/Abstract

摘要：以吉非替尼和厄洛替尼为代表的表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌治疗中发挥重要作用，然而在临床前和临床研究中发现，许多患者对此类药物存在原发性耐药或获得性耐药，使其临床应用受到一定限制。目前许多研究致力于延缓、逆转耐药以及开发新的靶点，为非小细胞肺癌的靶向治疗提供了更多的可能。

关键词:癌,非小细胞肺,突变,受体,表皮生长因子,抗药性,肿瘤,分子靶向治疗

Abstract:Gefitinib and erlotinib play important roles, which as the representative of the epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). However, preclinical and clinical studies find that many patients exist primary or acquired drug resistance to this drug, which limits the use of molecular targeted therapy drugs. At present, there are many studies focus on delaying or reversing drug resistance and developing new targets, which provide more potential for the molecular targeted therapy of NSCLC.

Key words:Carcinoma, non-small-cell lung,Mutation,Receptor, epidermal growth factor,Drug resistance, neoplasm,Molecular targeted therapy

张钰,周建国,马虎. 非小细胞肺癌分子靶向治疗及其耐药[J]. 国际肿瘤学杂志, 2016, 43(1): 45-48.

Zhang Yu, Zhou Jianguo, Ma Hu. Molecular targeted therapy for non-small cell lung cancer and drug resistance[J]. Journal of International Oncology, 2016, 43(1): 45-48.

参考文献

［1］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015［J］. CA Cancer J Clin, 2015, 65(1): 5-29. DOI:10.3322/caac.21254. ［2］ Jiang T, Zhou C. Clinical activity of the mutantselective EGFR inhibitor AZD9291 in patients with EGFR inhibitorresistant nonsmall cell lung cancer［J］. Transl Lung Cancer Res, 2014, 32(6): 8009. DOI:10.3978/j.issn.22186751.2014.08.02. ［3］ Wakelee H. ELCC 2014 news: phase Ⅰ study of CO1686 in patients with EGFR mutated recurrent, advanced NSCLC［C］. Switzerland, ELCC, 2014. ［4］ Sequist LV, Yang JC, Yamamoto N, et al. Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations［J］. J Clin Oncol, 2013, 31(27): 3327-3334. ［5］ Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4ALK fusion gene in nonsmallcell lung cancer［J］. Nature, 2007, 448(7153): 561-563. ［6］ Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmallcell lung cancer［J］. N Engl J Med, 2010, 363(18): 16931703. DOI:10.1056/NEJMoa1006448. ［7］ Solomon BJ, Gettinger SN, Riely GJ, et al. Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase Ⅲ study (PROFILE 1007) of advanced ALKpositive nonsmall cell lung cancer (NSCLC)［J］. J Clin Oncol, 2013, 31 suppl: abstr 8105. ［8］ Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFRmutant lung cancer by activation of Akt and EGFR［J］. Cancer Res, 2009, 69(8): 3256-3261. ［9］ Chang TH, Tsai MF, Su KY, et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor［J］. Am J Respir Crit Care Med, 2011, 183(8): 1071-1079. DOI:10.1164/rccm.201009-1440OC. ［10］ Winn RA, Tuder RM. "Unslugging" resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapy［J］. Am J Respir Crit Care Med, 2011, 183(8): 970972. DOI: 10.1164/rccm.2010121970ED. ［11］ Schmid K, Oehl N, Wrba F, et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases［J］. Clin Cancer Res, 2009, 15(14): 45544560. DOI:10.1158/1078-0432.CCR-09-0089. ［12］ Blumenschein GR, Smit EF, Planchard DA, et al. MEK114653: a randomized, multicenter, phase Ⅱ study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRASmutant advanced nonsmall cell lung cancer (NSCLC)［J］. J Clin Oncol, 2013, 31 Suppl: abstr 8029. ［13］ Chen Z, Sasaki T, Tan X, et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4ALK fusion oncogene［J］. Cancer Res, 2010, 70(23): 9827-9836. DOI:10.1158/0008-5472.CAN-10-1671. ［14］ Sasaki T, Jnne PA. New strategies for treatment of ALKrearranged nonsmall cell lung cancers［J］. Clin Cancer Res, 2011, 17(23): 7213-7218. DOI:10.1158/1078-0432.CCR-11-1404. ［15］ Wang M, Zhao J, Zhang LM, et al. Combined erlotinib and cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non- ［16］ Yamamoto N, Murakami H, Takahashi T, et al. Final results of a Japanese phase 1 trial evaluating a cmet inhibitor tivantinib in combination with an EGFR inhibitor erlotinib in advanced/metastatic nonsmall cell lung cancer (ARQ 197003/005 study)［J］. Ann Oncol, 2012, 23: 424. ［17］ Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced nonsmallcell lung cancer: a phase Ⅲ trial［J］. J Clin Oncol, 2012, 30(17): 20702078. DOI:10.1200/JCO.2011.39.2993. ［18］ VarellaGarcia M, Xu LG, Mahale SA,, et al. Nonsmallcell lung cancer: molecular targeted therapy and personalized medicine drug resistance, mechanisms, and strategies［J］. Pharmgenomics Pers Med, 2013, 6: 2536. DOI:10.2147/PGPM.S26058. ［19］ Garcia MV, Xu LG, Mahale S, et al. RET rearrangements detected by FISH in "pannegative" lung adenocarcinoma［J］. J Clin Oncol, 2013, 31 Suppl: abstr 8024.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[14]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[15]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.